Correction: Vascular endothelium derived endothelin-1 is required for normal heart function after chronic pressure overload in mice (PLoS ONE (2014) 9, 2 (e88730) DOI: 10.1371/journal.pone.0088730);Vascular endothelium derived endothelin-1 is required for normal heart function after chronic pressure overload in mice

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Heiden, Susi ^a   Vignon Zellweger, Nicolas ^a   Masuda, Shigeru ^b   Yagi, Keiko ^a   Nakayama, Kazuhiko ^a   Yanagisawa, Masashi ^c   Emoto, Noriaki ^a,b  

^a KOBE PHARMACEUTICAL UNIVERSITY   (Japan)

^b KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; CASPASE 3; CASPASE 8; COLLAGEN; ENDOTHELIN 1; MESSENGER RNA; PENTOXIFYLLINE; PROTEIN BCL 2; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL TISSUE; AORTA CONSTRICTION; APOPTOSIS; ARTICLE; CARDIOVASCULAR PARAMETERS; CELL SIZE; CONTROLLED STUDY; DISEASE MODEL; ECHOCARDIOGRAPHY; FEMALE; GENE EXPRESSION; HEART AFTERLOAD; HEART FAILURE; HEART FRACTIONAL SHORTENING; HEART FUNCTION; HEART MUSCLE CELL; HEART STRESS; HEART VENTRICLE HYPERTROPHY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; TREATMENT DURATION; VASCULAR ENDOTHELIUM; WILD TYPE;

ANIMALS; AORTA; APOPTOSIS; BLOOD PRESSURE; CARDIOMEGALY; ECHOCARDIOGRAPHY; ENDOTHELIN-1; ENDOTHELIUM, VASCULAR; FEMALE; GENE EXPRESSION PROFILING; GENOTYPE; HEART; HEART FAILURE; HEART RATE; MICE; MICE, KNOCKOUT; MYOCYTES, CARDIAC; PENTOXIFYLLINE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84895547020     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0099473     Document Type: Erratum

References (47)

1. Kohan DE, Rossi NF, Inscho EW, Pollock DM (2011) Regulation of blood pressure and salt homeostasis by endothelin. Physiol Rev 91: 1-77.
2. Löffler BM, Roux S, Kalina B, Clozel M, Clozel JP (1993) Influence of congestive heart failure on endothelin levels and receptors in rabbits. J Mol Cell Cardiol 25: 407-416. (Pubitemid 23172240)
3. Lerman A, Kubo SH, Tschumperlin LK, Burnett JC Jr (1992) Plasma endothelin concentrations in humans with end-stage heart failure and after heart transplantation. J Am Coll Cardiol 20: 849-853.
4. Gray GA, Webb DJ (1996) The endothelin system and its potential as a therapeutic target in cardiovascular disease. Pharmacol Ther 72: 109-148. (Pubitemid 26423301)
5. Hocher B, George I, Rebstock J, Bauch A, Schwarz A, et al. (1999) Endothelin System-Dependent Cardiac Remodeling in Renovascular Hypertension. Hypertension 33: 816-822. (Pubitemid 29140440)
6. Mulder P, Richard V, Bouchart F, Derumeaux G, Munter K, et al. (1998) Selective ETA receptor blockade prevents left ventricular remodeling and deterioration of cardiac function in experimental heart failure. Cardiovascular research 39: 600-608. (Pubitemid 28407592)
7. Sakai S, Miyauchi T, Kobayashi M, Yamaguchi I, Goto K, et al. (1996) Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature 384: 353-355. (Pubitemid 26408515)
8. Anand I, McMurray J, Cohn JN, Konstam MA, Notter T, et al. (2004) Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial. Lancet 364: 347E-354.
9. O'Connor CM, Gattis WA, Adams KF Jr, Hasselblad V, Chandler B, et al. (2003) Tezosentan in patients with acute heart failure and acute coronary syndromes: results of the Randomized Intravenous TeZosentan Study (RITZ-4). J Am Coll Cardiol 41: 1452-1457. (Pubitemid 36543358)
10. Kirkby NS, Hadoke PW, Bagnall AJ, Webb DJ (2008) The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house? Br J Pharmacol 153: 1105-1119. (Pubitemid 351415492)
11. Vignon-Zellweger N, Relle K, Kienlen E, Alter M, Seider P, et al. (2011) Endothelin-1 overexpression restores diastolic function in eNOS knockout mice. J Hypertens 29: 961-970.
12. Kakita T, Hasegawa K, Iwai-Kanai E, Adachi S, Morimoto T, et al. (2001) Calcineurin pathway is required for endothelin-1-mediated protection against oxidant stress-induced apoptosis in cardiac myocytes. Circ Res 88: 1239-1246. (Pubitemid 32587839)
13. Ogata Y, Takahashi M, Ueno S, Takeuchi K, Okada T, et al. (2003) Antiapoptotic effect of endothelin-1 in rat cardiomyocytes in vitro. Hypertension 41: 1156-1163. (Pubitemid 36548619)
14. Zhao XS, Pan W, Bekeredjian R, Shohet RV (2006) Endogenous endothelin-1 is required for cardiomyocyte survival in vivo. Circulation 114: 830-837. (Pubitemid 44268233)
15. Kisanuki YY, Emoto N, Ohuchi T, Widyantoro B, Yagi K, et al. (2010) Low blood pressure in endothelial cell-specific endothelin 1 knockout mice. Hypertension 56: 121-128.
16. Shohet RV, Kisanuki YY, Zhao XS, Siddiquee Z, Franco F, et al. (2004) Mice with cardiomyocyte-specific disruption of the endothelin-1 gene are resistant to hyperthyroid cardiac hypertrophy. Proc Natl Acad Sci U S A 101: 2088-2093. (Pubitemid 38229019)
17. Widyantoro B, Emoto N, Nakayama K, Anggrahini DW, Adiarto S, et al. (2010) Endothelial cell-derived endothelin-1 promotes cardiac fibrosis in diabetic hearts through stimulation of endothelial-to-mesenchymal transition. Circulation 121: 2407-2418.
18. Polderman KH, Stehouwer CD, van Kamp GJ, Dekker GA, Verheugt FW, et al. (1993) Influence of sex hormones on plasma endothelin levels. Ann Intern Med 118: 429-432. (Pubitemid 23081052)
19. Kedzierski RM, Grayburn PA, Kisanuki YY, Williams CS, Hammer RE, et al. (2003) Cardiomyocyte-specific endothelin A receptor knockout mice have normal cardiac function and an unaltered hypertrophic response to angiotensin II and isoproterenol. Mol Cell Biol 23: 8226-8232. (Pubitemid 37377512)
20. Adiarto S, Heiden S, Vignon-Zellweger N, Nakayama K, Yagi K, et al. (2012) ET-1 from endothelial cells is required for complete angiotensin II-induced cardiac fibrosis and hypertrophy. Life Sci 91: 651-657.
21. Chen QM, Tu VC, Purdon S, Wood J, Dilley T (2001) Molecular mechanisms of cardiac hypertrophy induced by toxicants. Cardiovasc Toxicol 1: 267-283.
22. Fliegner D, Schubert C, Penkalla A, Witt H, Kararigas G, et al. (2010) Female sex and estrogen receptor-beta attenuate cardiac remodeling and apoptosis in pressure overload. Am J Physiol Regul Integr Comp Physiol 298: R1597-R1606.
23. Condorelli G, Morisco C, Stassi G, Notte A, Farina F, et al. (1999) Increased Cardiomyocyte Apoptosis and Changes in Proapoptotic and Antiapoptotic Genes bax and bcl-2 During Left Ventricular Adaptations to Chronic Pressure Overload in the Rat. Circulation 99: 3071-3078. (Pubitemid 29270439)
24. Moorjani N, Catarino P, Trabzuni D, Saleh S, Moorji A, et al. (2007) Upregulation of Bcl-2 proteins during the transition to pressure overload-induced heart failure. Int J Cardiol 116: 27-33. (Pubitemid 46227602)
25. Wei H, Bedja D, Koitabashi N, Xing D, Chen J, et al. (2012) Endothelial expression of hypoxia-inducible factor 1 protects the murine heart and aorta from pressure overload by suppression of TGF- b signaling. Proc Natl Acad Sci U S A 109: E841-E850.
26. Bryan PM, Xu X, Dickey DM, Chen Y, Potter LR (2007) Renal hyporesponsiveness to atrial natriuretic peptide in congestive heart failure results from reduced atrial natriuretic peptide receptor concentrations. Am J Physiol Renal Physiol 292: F1636-F1644. (Pubitemid 46701892)
27. Dickey DM, Flora DR, Bryan PM, Xu X, Chen Y, et al. (2007) Differential regulation of membrane guanylyl cyclases in congestive heart failure: natriuretic peptide receptor (NPR)-B, Not NPR-A, is the predominant natriuretic peptide receptor in the failing heart. Endocrinology 148: 3518-3522. (Pubitemid 46997008)
28. Torre-Amione G, Kapadia S, Benedict C, Oral H, Young JB, et al. (1996) Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 27: 1201-1206. (Pubitemid 26117714)
29. Shimojo N, Jesmin S, Zaedi S, Soma M, Maeda S, et al. (2006) Changes in Important Apoptosis-Related Molecules in the Endothelin-1-Induced Hypertrophied Cardiomyocytes: Effect of the Pretreatment with Eicosapentaenoic Acid. Exp Biol Med (Maywood) 231: 932-936. (Pubitemid 43845555)
30. Kittikulsuth W, Pollock JS, Pollock DM (2011) Sex differences in renal medullary endothelin receptor function in angiotensin II hypertensive rats. Hypertension 58: 212-218.
31. Kittikulsuth W, Looney SW, Pollock DM (2013) Endothelin ET(B) receptors contribute to sex differences in blood pressure elevation in angiotensin II hypertensive rats on a high-salt diet. Clin Exp Pharmacol Physiol 40: 362-370.
32. Bahrmann P, Hengst UM, Richartz BM, Figulla HR (2004) Pentoxifylline in ischemic, hypertensive and idiopathic-dilated cardiomyopathy: effects on left-ventricular function, inflammatory cytokines and symptoms. Eur J Heart Fail 6: 195-201. (Pubitemid 38249363)
33. Skudicky D, Bergemann A, Sliwa K, Candy G, Sareli P (2001) Beneficial Effects of Pentoxifylline in Patients With Idiopathic Dilated Cardiomyopathy Treated With Angiotensin-Converting Enzyme Inhibitors and Carvedilol. Circulation 103: 1083-1088. (Pubitemid 32200181)
34. Sliwa K, Skudicky D, Candy G, Bergemann A, Hopley M, et al. 2002) The addition of pentoxifylline to conventional therapy improves outcome in patients with peripartum cardiomyopathy. Eur J Heart Fail 4: 305-309. (Pubitemid 35190355)
35. Sliwa K, Woodiwiss A, Libhaber A, Zhanje F, Libhaber C, et al. (2003) C-reactive protein predicts response to pentoxifylline in patients with idiopathic dilated cardiomyopathy. Eur J Heart Fail 6: 731-734.
36. Sliwa K, Woodiwiss A, Kone VN, Candy G, Badenhorst D, et al2004) Therapy of Ischemic Cardiomyopathy With the Immunomodulating Agent Pentoxifylline. Circulation 109: 750-755. (Pubitemid 38222895)
37. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT, et al. (2003) Randomized, doubleblind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the Anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 107: 3133-3140. (Pubitemid 36793081)
38. Mann D, McMurray J, Packer M, Swedberg K, Borer J, et al. (2004) Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 109: 1594-1602. (Pubitemid 38451714)
39. Kurrelmeyer K, Michael L, Baumgarten G, Taffet G, Peschon J, et al. (2000) Endogenous tumor necrosis factor protects the adult cardiac myocyte against ischemic-induced apoptosis in a murine model of acute myocardial infarction. Proc Natl Acad Sci U S A 97: 5456-5461. (Pubitemid 30313740)
40. Osterreicher J, Králik M, Navrátil L, Vávrová J, Skopek J, et al. (2001) Apoptosis and bcl-2 expression in irradiated lungs and the effect of pentoxifylline. Acta Medica (Hradec Kralove) 44: 125-130.
41. Wann BP, Boucher M, Kaloustian S, Nim S, Godbout R, et al. (2006) Apoptosis detected in the amygdala following myocardial infarction in the rat. Biol Psychiatry 59: 430-433. (Pubitemid 43289222)
42. Shaw S, Shah M, Williams S, Fildes J (2009) Immunological mechanisms of pentoxifylline in chronic heart failure. Eur J Heart Fail 11: 113-118.
43. Gahlot S, Khan MA, Rishi L, Majumdar S (2010) Pentoxifylline augments TRAIL/Apo2L mediated apoptosis in cutaneous T cell lymphoma (HuT-78 and MyLa) by modulating the expression of antiapoptotic proteins and death receptors. Biochem Pharmacol 80: 1650-1661.
44. Gómez-Contreras P, Hernández-Flores G, Ortiz-Lazareno P, del Toro-Arreola S, Delgado-Rizo V, et al. (2006) In vitro Induction of Apoptosis in U937 Cells by Perillyl Alcohol with Sensitization by Pentoxifylline: Increased BCL-2 and BAX Protein Expression. Chemotherapy 52: 308-315. (Pubitemid 44608669)
45. Nicklasson M, Bjorkman S, Roth B, Jonsson M, Hoglund P (2002) Stereoselective metabolism of pentoxifylline in vitro and in vivo in humans. Chirality 14: 652.
46. Nisi A, Panfili M, De Rosa G, Boffa G, Groppa F, et al. (2012) Pharmacokinetics of Pentoxifylline and Its Main Metabolites in Patients With Different Degrees of Heart Failure Following a Single Dose of a Modified-Release Formulation. J Clin Pharmacol.
47. Fantin M, Quintieri L, Kúsz E, Kis E, Glavinas H, et al. (2006) Pentoxifylline and its major oxidative metabolites exhibit different pharmacological properties. Eur J Pharmacol 535: 301-309.